Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
NCT06463171
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer Non-small Cell Stage IV
Interventions
DRUG:
Almonertinib
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Collaborators
[object Object]
[object Object]